Loading...
•
Sep 30, 2020
Keros Q3 2020 Earnings Report
Keros Therapeutics reported financial results for the third quarter of 2020.
Key Takeaways
Keros Therapeutics reported a net loss of $12.0 million in the third quarter of 2020. Research and development expenses were $8.4 million, and general and administrative expenses were $3.6 million. Cash and cash equivalents as of September 30, 2020, were $133.8 million.
Dosed the first patients in Phase 2 clinical trial of KER-050.
Regained worldwide rights to development programs in metabolic diseases.
Completed expanded Phase 1 clinical trial of KER-047.
Expects to have multiple ongoing Phase 2 clinical trials in 2021.
Keros
Keros
Forward Guidance
Keros expects that the cash and cash equivalents it had on hand at September 30, 2020 will fund its operating expenses and capital expenditure requirements into the second half of 2022.